CRLCharles River Laboratories

Health care · Research Services · NYSE

We began operating in 1947 and, since then, have undergone several changes to our business structure. 10-K, Item 1

Employees: 19,700
Headquarters: Wilmington, MA
CEO: Birgit Girshick
Next results: around Jan 12, 2027

RevenueFY2016–25 $4.0B−0.9% FY2024: $4.0B 10-K FY2025 · XBRL Net incomeFY2016–25 −$144.3M FY2024: $22.2M 10-K FY2025 · XBRL Free cash flowFY2016–25 $518.5M+3.4% FY2024: $501.6M 10-K FY2025 · XBRL Operating marginFY2016–25 0.6%−5.0 pts 14.1% in FY2016 10-K FY2025 · XBRL

What changed

10-K filed Feb 18, 2026 against Feb 19, 2025

Area	What changed	Source
Risk factors	21 new paragraphs, nothing like them in the previous 10-K	10-K Item 1A
Accounting checks	11 other checks clear	10-K · XBRL
Insiders	1 open-market buy in the last 90 days	Form 4
Filings	3 in the last 30 days	EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

What's new, in their words

10-K filed Feb 18, 2026

Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-19. Quoted as filed.

We leverage software and hardware solutions from technology and services providers, including software-as-a-service and public cloud infrastructure, who have been subject to cybersecurity incidents in the past and may have incidents or breaches in the future. As of the date of this filing, to our knowledge, no prior cybersecurity…
10-K, Item 1A

All 21 new paragraphs →

Accounting checks

latest 10-K

11 of 11 clear 0 worth a look. Checks, not verdicts.

✓
Receivables -1.7% vs revenue -0.9% (-0.8 pts)
✓
Cash from operations $737.6M vs net income −$144.3M (FY ending 2025-12-27)
✓
Inventory +7.4% vs revenue -0.9% (+8.2 pts)
✓
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
✓
No statement of substantial doubt about going concern
✓
No 8-K item 4.02 in the last 2 years
✓
No NT 10-K or NT 10-Q in the last 2 years
✓
The same matters as last year: Annual Goodwill Impairment Assessment - Biologics Solutions Reporting Unit; Revenue Recognition using the Cost-to-Cost Method - Discovery and Safety Assessment
✓
No sentence in the 10-K concludes that controls were not effective because of a material weakness
✓
No 8-K item 2.06 in the last 2 years
✓
No 8-K item 1.03 in the last 2 years

How each check works, with sources →

In the last 30 days

All filings →

Nov 9, 20268-K Regulation FD disclosure 8-K item 7.01
Nov 4, 20268-K Quarterly results 8-K item 2.02
Nov 4, 202610-Q Quarterly report (10-Q) period ended Sep 26, 2026

Get an email when this changes: new risk paragraphs, accounting items, insider purchases, a new 10-K or 10-Q. RSS feed

Work on CRL in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/CRL/export.csv") into a cell.